Enterprise Trust & Investment’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY.RT
PCM
ACM
FCM
BFS
LGP
CS
LCM
NCM
Enterprise Trust & Investment's BMY.RT Position: Q4 2020 in Review
Enterprise Trust & Investment sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 17,650 shares — an estimated $40K sold.
Enterprise Trust & Investment first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $70K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.
- Enterprise Trust & Investment reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
- Enterprise Trust & Investment sold 17,650 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $40K.
- Enterprise Trust & Investment first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
- Enterprise Trust & Investment's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $70K in Q1 2020.
- 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.
Based on Enterprise Trust & Investment's 13F filing for Q4 2020, filed 14 Jan 2021.